Date:5/2/2012

s and attributes of the company's product pipeline, including the ability of the company's tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical and developmental studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and the timing thereof; unanticipated costs or delays in research and development efforts; the applicability of initial next generation sequencing studies to future results; the success of our NGS efforts; our ability to use NGS to obtain the objectives of the strategic alliance; the risk that we may not obtain or maintain reimbursement for our existing tests and any future tests we may develop, both domestically and abroad;  our ability to compete against third parties; the risks and uncertainties associated with the regulation of our tests by the FDA and other agencies abroad; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-K for the period ended December 31, 2011. These forward- looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

'/>"/>

SOURCE Genomic Health, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
2. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
3. Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
4. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
5. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
6. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
7. Genomic Technologies: Market Insights for Life Science Suppliers
8. SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System
9. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
10. New England Biolabs and Rubicon Genomics Enter into Distribution Agreement for Single Cell Amplification Products
11. Center for Proteomics at the Translational Genomics Research Institute (TGen) Selected as Waters Center of Innovation